BMBernd Metzner

Bernd Metzner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bernd Metzner has a total of 227 co-authors. Here are the top co-authors by number of shared publications:

  • Bernd Rosien

    Department of Oncology and Hematology, Klinikum Oldenburg University Clinic Oldenburg Germany

    7 shared publications
  • Jochen Casper

    Department of Oncology and Hematology, Klinikum Oldenburg University Clinic Oldenburg Germany

    7 shared publications
  • Ruth Thole

    Department of Oncology and Hematology, Klinikum Oldenburg University Clinic Oldenburg Germany

    5 shared publications
  • Andrea Renzelmann

    Department of Oncology and Hematology, Klinikum Oldenburg University Clinic Oldenburg Germany

    4 shared publications
  • Christoph Kimmich

    Department of Oncology and Hematology, Klinikum Oldenburg University Clinic Oldenburg Germany

    4 shared publications
  • Thomas H. Müller

    Red Cross Blood Transfusion Service NSTOB Oldenburg Germany

    4 shared publications

Latest Publications

  • Intensity of endogenous thrombocytopenia after autologous stem cell transplantation in patients prophylactically transfused with platelets

    by Andreas Voß, Andrea Doescher, Hans‐Hermann Kapels, Axel Seltsam, Andreas Greinacher, Bernd Metzner, Thomas H. Müller

    Large clinical trials have demonstrated that some patient groups with hypoproliferative thrombocytopenia benefit from prophylactic platelet transfusions, while in others, a therapeutic transfusion regimen might be sufficient. The remaining capacity to generate endogenous platelets might be helpful to select the platelet transfusion regimen. We assessed whether the recently described method of digital droplet polymerase chain reaction (PCR) can be used to assess the endogenous platelet levels in two groups of patients undergoing high-dose chemotherapy with autologous stem cell transplantation (ASCT). Multiple myeloma (n = 22) patients received high-dose melphalan alone (HDMA); lymphoma patients (n = 15) received BEAM or TEAM (B/TEAM) conditioning. Patients with a total platelet count + -cell dose in the graft was inversely correlated with the intensity of endogenous thrombocytopenia in B/TEAM-treated patients. Monitoring endogenous platelet counts detects the direct effects of myelosuppressive chemotherapies on platelet regeneration. This approach may help to develop a platelet transfusion regimen tailored to specific patient groups.

  • Long‐term outcome in patients with mantle cell lymphoma following high‐dose therapy and autologous stem cell transplantation

    by Bernd Metzner, Thomas H. Müller, Jochen Casper, Christoph Kimmich, Claus‐Henning Köhne, Eduard Petershofen, Andrea Renzelmann, Ruth Thole, Andreas Voss, Martin Dreyling, et al.

    Background: Long‐term clinical and molecular remissions in patients with mantle cell lymphoma (MCL) after autologous stem cell transplantation (ASCT) have been evaluated in only a few studies.Design and Methods: Sixty‐five patients with MCL received ASCT (54 first‐line ASCT, 10 second‐line ASCT, and 1 third‐line ASCT). In the case of long‐term remission (≥5 years; n = 27), peripheral blood was tested for minimal residual disease (MRD) by t(11;14)‐ and IGH‐PCR at the last follow‐up.Results: Ten‐year overall survival (OS), progression‐free survival (PFS), and freedom from progression (FFP) after first‐line ASCT were 64%, 52%, and 59% versus after second‐line ASCT 50%, 20%, and 20%, respectively. Five‐year OS, PFS, and FFP for the first‐line cohort were 79%, 63%, and 69%, respectively. Five‐year OS, PFS, and FFP after second‐line ASCT were 60%, 30%, and 30%, respectively. Treatment‐related mortality (3 months after ASCT) was 1.5%. So far 26 patients developed sustained long‐term clinical and molecular complete remissions of up to 19 years following ASCT in first treatment line.Conclusion: Sustained long‐term clinical and molecular remissions are achievable following ASCT.


  • Herpes zoster prophylaxis with low‐dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation

    by Emin Abbasov, Bernd Metzner, Thomas H. Müller, Jochen Casper, Christoph Kimmich, Eduard K. Petershofen, Andrea Renzelmann, Bernd Rosien, Ruth Thole, Andreas Voß, et al.

    Background: Herpes zoster (HZ) is a frequent complication after autologous stem cell transplantation (ASCT). The option of zoster prophylaxis with an antiviral drug is described in the literature, but there is no consensus on the drug and the dosage.Patients and Methods: We analyzed the records of 310 patients treated with ASCT who were controlled regularly regarding HZ inter alia for at least 24 months following ASCT. Since 01/2015 patients received prophylactic low‐dose acyclovir (400 mg per day) during the first 12 months following discharge after ASCT (n = 107).Results: Twenty percent of patients without this kind of prophylaxis and 2.8% of patients with prophylaxis developed HZ (p < .001). No patient with this prophylaxis developed HZ in the first year after ASCT, 2.8% of patients in the second year after ASCT. A prognostic factor was the kind of diagnosis: 30% of lymphoma patients and 14% of myeloma patients developed HZ in the first 24 months after ASCT without prophylaxis, but only 6.3% and 0% of patients with prophylaxis, respectively. Neither an increase of HZ cases following prophylaxis nor acyclovir refractory HZ cases were observed.Conclusions: Zoster prophylaxis with low‐dose acyclovir over 12 months after ASCT is effective and well tolerated.


  • Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease

    by Bernd Metzner, Jutta Welzel, Thomas H. Müller, Jochen Casper, Christoph Kimmich, Eduard K. Petershofen, Andrea Renzelmann, Bernd Rosien, Ruth Thole, Andreas Voss, et al.

    Purpose The prognosis of an early relapse of diffuse large B-cell lymphoma (DLBCL) appears to be poor following autologous stem cell transplantation (ASCT). The aim of this study is to contribute data to the open question on whether additional radiotherapy can improve the outcome. Patients and methods Forty-eight patients with an early relapse (median 4 months after the end of initial immunochemotherapy, range 1–11) of DLBCL have been treated in our institution with high-dose therapy (usually the BEAM protocol) and ASCT since 2008 (median age 61 years, range 28–73). Twenty-three patients received ASCT in a second treatment line, 25 in a third line (19 refractory to second-line salvage therapy, 5 after second relapse). Fifteen of these 48 patients received radiotherapy (36–50 Gy, median 40) of residual masses after ASCT. Results Three-year overall survival (OS) and progression-free survival (PFS) after second-line ASCT were 61 and 57%, after third-line ASCT 47 and 44%, respectively, without significant differences. A prognostic factor was the International Prognostic Index (IPI) at the start of salvage therapy. Three-year OS and PFS in low-risk patients were 69 and 69%, in low-intermediate-risk 63 and 53%, and in high-intermediate-risk 23 and 23%, respectively (p = 0.033). Twenty-three patients achieved a sustained complete remission (13–146 months, median 62). Conclusion Sustained long-term remissions can be achieved in patients with early relapse of DLBCL following ASCT in a second or third treatment line, particularly in patients with low- and low-intermediate-risk IPI, following radiotherapy of residual disease after ASCT. Further investigations are required to clarify which patients need an alternative therapy (potentially CAR T‑cells or allogeneic transplantation).


  • Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation

    by Bernd Metzner, Christiane Pott, Thomas H. Müller, Jochen Casper, Christoph Kimmich, Eduard K. Petershofen, Andrea Renzelmann, Bernd Rosien, Ruth Thole, Andreas Voß, et al.

    Objective: To contribute data on long‐term outcome and potential curative impact of ASCT in FL, especially following HDT with the BEAM protocol (BCNU, etoposide, cytarabine and melphalan), given very limited data on this topic in the literature.Patients and methods: Patients with FL (n = 76) were treated in our institution with HDT and ASCT. In the case of long‐term remission (≥8 years), peripheral blood was tested for minimal residual disease by t(14;18)‐ and IGH‐PCR, including the last follow‐up.Results: 10‐year overall survival, progression‐free survival, and freedom from progression (FFP) after first‐line ASCT (n = 20) were 80%, 60%, and 69%, after second‐line ASCT (n = 48, following BEAM) 66%, 38%, and 41%, after third/fourth‐line ASCT (n = 8) 33%, 25%, and 25%, respectively. Prognostic factors for FFP were treatment line and FLIPI (Follicular Lymphoma International Prognostic Index). 10‐year FFP for second‐line ASCT and low‐risk FLIPI at relapse was 69%, intermediate‐risk 28%, and high‐risk 25% (P < .05). 26 patients developed sustained long‐term clinical and molecular remissions of up to 27 years.Conclusions: Sustained long‐term clinical and molecular complete remissions up to 27 years can be achieved following ASCT (including HDT with BEAM in second treatment line), indicating a potential curative impact of ASCT in FL.


  • Open Access

    Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM

    by Friederike Bachmann, Martin Schreder, Monika Engelhardt, Christian Langer, Denise Wolleschak, Lars Olof Mügge, Heinz Dürk, Kerstin Schäfer-Eckart, Igor Wolfgang Blau, Martin Gramatzki, et al.

    Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group.


  • A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

    by Norbert Schmitz, Lorenz H Truemper, Krimo Bouabdallah, Marita Ziepert, Mathieu Leclerc, Guillaume Cartron, Arnaud Jaccard, Peter Reimer, Eva Maria Wagner-Drouet, Martin Wilhelm, et al.

    Standard first-line therapy for younger patients with peripheral T-cell lymphoma consists of six courses of CHOP or CHOEP consolidated by high-dose therapy and autologous stem cell transplantation (AutoSCT). We hypothesized that consolidative allogeneic transplantation (AlloSCT) could improve outcome. 104 patients with nodal peripheral T-cell lymphoma except ALK+ ALCL, 18 to 60 years of age, all stages and IPI scores except stage 1 and aaIPI 0, were randomized to receive 4 x CHOEP and 1 x DHAP followed by high-dose therapy and AutoSCT or myeloablative conditioning and AlloSCT. The primary endpoint was event-free survival (EFS) at three years. After a median follow-up of 42 months, 3-year EFS of patients undergoing AlloSCT was 43% (95% confidence interval [CI]: 29%; 57%) as compared to 38% (95% CI: 25%; 52%) after AutoSCT. Overall survival at 3 years was 57% (95% CI: 43%; 71%) versus 70% (95% CI: 57%; 82%) after AlloSCT or AutoSCT, without significant differences between treatment arms. None of 21 responding patients proceeding to AlloSCT as opposed to 13 of 36 patients (36%) proceeding to AutoSCT relapsed. Eight of 26 patients (31%) and none of 41 patients died due to transplant-related toxicity after allogeneic and autologous transplantation, respectively. In younger patients with T-cell lymphoma standard chemotherapy consolidated by autologous or allogeneic transplantation results in comparable survival. The strong graft-versus-lymphoma effect after AlloSCT was counterbalanced by transplant-related mortality. CHO(E)P followed by AutoSCT remains the preferred treatment option for transplant-eligible patients. AlloSCT is the treatment of choice for relapsing patients also after AutoSCT.


  • Open Access

    Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

    by Hermann Einsele, Monika Engelhardt, Christoph Tapprich, Jürgen Müller, Peter Liebisch, Christian Langer, Martin Kropff, Lars O. Mügge, Wolfram Jung, Hans‐Heinrich Wolf, et al.

    Summary: We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy in previously untreated multiple myeloma patients. A total of 414 patients received three 21‐day cycles of VCD prior to autologous stem‐cell transplantation (ASCT). Most common grade ≥3 adverse events were leucopenia (31·4%) and thrombocytopenia (6·8%). The overall response rate (ORR) by investigator‐based assessment was 85·4%. Most patients (74%) underwent successful central laboratory‐based molecular cytogenetic analysis. No clinically relevant differences in ORR post‐induction were seen between patients with or without high‐risk cytogenetic abnormalities (86·2% vs. 84·3%). Further follow‐up data are available for 113 patients receiving ASCT who were included in a prospective consolidation trial (median follow‐up, 55·5 months); median progression‐free survival (PFS) was 35·3 months and median overall survival (OS) was not reached. In patients with high‐risk versus standard‐risk cytogenetics, median PFS was 19·9 vs. 43·6 months (P < 0·0001), and median OS was 54·7 months versus not reached (P = 0·0022). VCD is an effective and tolerable induction regimen; results suggest that VCD induces high response rates independently of cytogenetic risk status, but after long‐term follow‐up, cytogenetic high risk is associated with markedly reduced PFS and OS post‐ASCT.


  • Open Access

    Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma

    by Stefan Knop, Peter Liebisch, Holger Hebart, Ernst Holler, Monika Engelhardt, Bernd Metzner, Dietrich Peest, Walter Aulitzky, Donald W. Bunjes, Christian Straka, et al.

    Background In multiple myeloma (MM), the introduction of novel compounds into first-line intensive treatment pathways has clearly improved patients’ prognosis. Very recently however, specific molecular cytogenetic abnormalities, lactate dehydrogenase elevation and International Staging System 3 disease were identified to be associated with dismal prognosis despite upfront autologous (auto) stem cell transplant (SCT). Consolidative allogeneic (allo) following initial auto SCT was shown to extend progression-free survival (PFS) as well as overall survival (OS) in some prospective studies on newly diagnosed MM patients (pts). Relatively little is known on the impact of cytogenetic features other than chromosome 13q deletion (del13q) on the outcomes of pts undergoing upfront auto followed by allo (auto/allo) SCT. Patients and methods When the DSMM V treatment program was designed del13q detected by fluorescence in situ hybridisation (FISH) was accepted as one of the distinct risk factors in MM. We therefore used FISH del13q to define the study’s “high-risk” group and aimed to compare tandem high-dose melphalan 200 mg/m² (Mel) with one cycle of Mel followed by reduced-intensity conditioning (RIC) allo SCT. Allocation to either transplant regimen was by availability of an HLA-matched (at least 9/10 matches) related (MRD) or unrelated donor (MUD). Initially, all pts underwent non-novel compound cytoreduction and chemomobilization of peripheral blood stem cells (PBSC). RIC allo SCT was prepared by fludarabine and melphalan (plus ATG in MUD cases). PFS was the primary endpoint. The study was powered to detect an improvement of 2-year PFS from 20% (tandem Mel) to 40.3% (HR, 1.769). Results 199 out of 225 del13q pts with a median age of 53 (range, 30 – 60) yrs who had been enrolled between 10/2001 and 03/2007, were included in the intent-to treat population. Allo SCT was performed in 126/199 pts (63%), 74 of whom (59%) received MUD allografts. At a median follow-up of 49.2 months (mo), 2-year PFS (calculated from day 1 of second SCT) was 59% with auto/allo SCT versus 47% with tandem Mel. Median PFS with auto/allo SCT was 34.5 mo versus 21.8 mo, respectively (p=.005). Two-year non-relapse mortality (NRM) associated with auto/allo SCT was 11.9%. As of yet, there is no difference in OS between the groups, with the median not yet reached for either transplant modality. PFS/OS in auto/allo SCT were independent of donor source (MRD vs MUD). As definitions of cytogenetic risk have evolved over time, we analyzed further FISH abnormalities in pts’ baseline samples: in addition to uniform del13q, 13.6% of pts displayed del17p. Median PFS for del13q/del17p pts after HD Mel was 6 mo versus not reached with auto/allo SCT, respectively (p=.0002). Median OS in del13q/del17p after HD Mel was 23.4 mo versus not reached, respectively (p=.011). In translocation (4;14)/del13q pts (20.7%), median PFS with tandem Mel was 19.3 mo versus 19.1 with auto/allo SCT, respectively (p=.251). Conclusions This prospective trial shows auto/allo SCT to significantly extend PFS when compared to tandem HD Mel in a large cohort of del13q MM pts. It is the first study to demonstrate allo SCT in MM can be safely performed from matched unrelated donors at a reasonable rate of NRM. Utilizing a comprehensive set of FISH cytogenetics, our data for the first time demonstrate allo SCT to specifically benefit patients with high-risk features (del13q/del17p). Incremental gain of PFS when compared to tandem Mel was more than 20 months. Extended OS data on the whole study will be presented.